Concord Biotech Limited is gearing up for its much-anticipated Initial Public Offering (IPO) through a book-built issue. The IPO is scheduled to run from August 04 to August 08, 2023, with a share price range of ₹705 to ₹741. Investors can participate with a minimum order of 20 shares.
The IPO will comprise 20,925,652 shares with a face value of Rs. 1 each, potentially raising funds of up to ₹1551 crore for Concord Biotech Limited. Let’s delve into the details of their IPO set to hit the market in August 2023.
About Concord Biotech Limited
Incorporated in 1984, Concord Biotech Limited is an Indian biopharma company known for its R&D focus. It is a leading global developer and manufacturer of fermentation-based APIs in immunosuppressants and oncology, with a substantial market share based on volume in 2022.. The company exports its products to over 70 countries, including the USA, India, Europe, and Japan. Concord Biotech manufactures APIs through fermentation and semi-synthetic processes and offers a wide range of therapeutic products, including Immunosuppressants, Anti-bacterial, Oncology, Antifungals, and more. It also maintains a robust pipeline of products under development.
Concord Biotech IPO Issue Details
| Issue Type | Book Built IPO Issue |
| Issue Opens | 4th August 2023 |
| Issue Closes | 8th August 2023 |
| Face Value | Rs 1 Per Share |
| Issue Price | Rs 705 to Rs 741 Per Share |
| Issue Size | 20,925,652 Shares (Rs 1551 crores) |
| Minimum Order Quantity | 20 Shares |
| Listing | NSE, BSE |
Purpose of the Issue
The Offer has two main objectives:
- To realize the advantages of listing the Equity Shares on the Stock Exchanges.
- To conduct the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.
Concord Biotech Limited — Company Contact Details
- Registered & Corporate Office: 1482-86, Trasad Road Dholka, Ahmedabad – 382225
- Telephone: 079-6813 8700
- Website: http://www.concordbiotech.com/
Concord Biotech Limited IPO – Lead Managers of the Issue
Kotak Mahindra Capital Company Limited
- Office Address: 27 BKC, C-27, G Block, Bandra Kurla Complex, Bandra(E), Mumbai 400051
- Telephone: +91-22-4336 0000
- Email: ajay.vaidya@kotak.com
Citigroup Global Markets India Private Limited
- Office Address: 1202, 12th Floor, First International Financial Centre, G Block, Bkc, Bandra (East), Mumbai, 400098
- Telephone: + 91 02 2631 9999
- Email: dlf.ipo@citigroup.com
Jefferies India Private Limited
- Office Address: 42/43, 2 North Avenue, Maker Maxity, Bandra-Kurla Complex, Bandra (East), Mumbai 400051
- Telephone: (+91 22) 4356 6000
- Email: syngene.ipo@jefferies.com
Concord Biotech IPO – Registrar of the Issue
Link Intime India Private Ltd
- Telephone: +91-22-4918 6270
- Email: concordbiotech.ipo@linkintime.co.in
- Website: https://linkintime.co.in/mipo/ipoallotment.html
Concord Biotech Limited IPO Issue Prospectus
Click here to read the Final Prospectus of this IPO Issue.
Disclaimer: Investingly just provides basic information as update about the issues. Investingly never gives advices or recommendations to anyone. Investments into securities are subject to market risk. Please read the offer and issue documents carefully before investing. It is also advised to consult your financial advisor for necessary suggestions.
